Abstract:Abstract High-risk neuroblastoma is one of the most difficult to treat pediatric cancers, with a survival rate of only about 50% and significant long-term consequences from current chemotherapy. Preclinical models such as cell lines and mice are the backbone of drug development and experimental-mechanistic oncology, but the development of new treatments is hampered in part by a lack of understanding of the direct clinical relevance of such data collected in preclinical models. Despite this, few formal methods have been developed to determine how these various models represent/resemble primary patient tumors. Here, we present the first comprehensive single-cell RNA-seq analysis of neuroblastoma across an extensive cohort of patient tumors and a variety of preclinical model systems (n = 126 total samples assembled - the largest cohort of its kind). By building an innovative unsupervised machine learning method, which we term “automatic consensus nonnegative matrix factorization” (acNMF), we have integrated and contrasted the transcriptional landscapes of patient tumors with those of cell lines, patient-derived xenografts (PDX), and genetic mouse models (GEMM).Using these tools, we discovered the dominant adrenergic gene expression programs found in neuroblastoma patient tumors were preserved across all preclinical models. However, the presumptive chemo-resistant mesenchymal-like programs, while identifiable in cell lines, were primarily restricted to subpopulations of cancer-associated fibroblasts and Schwann-like cells in vivo. Surprisingly, a mesenchymal-like program could be acutely chemotherapy-induced in GEMM and was evident in pre-treated patient and PDX samples, suggesting a previously uncharacterized mechanism of therapy escape. In addition to these core findings, our computational tools were able to further delineate the classical neuroblastoma adrenergic and mesenchymal gene expression programs, discovering for example, novel subpopulations of cancer associated fibroblasts. These behaviors were conserved across tumors and most preclinical models, which we validated by RNA in situ hybridization, which is a high resolution ultra sensitive spatial transcriptomics technology. Our work cautions against overreliance on traditional preclinical models without recognizing their limitations and we offer a nuanced, high-resolution view of neuroblastoma pre-clinical systems for advancing therapeutic development. We have launched an open-source web resource, featuring this integrated map to aid the scientific community in further exploration of these data and hypothesis generation (available at http://pscb.stjude.org). Citation Format: Rich Chapple, Xueying Liu, Sivaraman Natarajan, Margaret I. Alexander, Yuna Kim, Anand Patel, Christy W. LaFlamme, Min Pan, William C. Wright, Hyeong-Min Lee, Yinwen Zhang, Meifen Lu, Selene C. Koo, Courtney Long, John Harper, Chandra Savage, Melissa D. Johnson, Thomas Confer, Walter J. Akers, Michael A. Dyer, Heather Sheppard, John Easton, Paul Geeleher. A novel unsupervised machine learning model applied to neuroblastoma single-cell RNA-seq data reveals a drug-induced mesenchymal-like gene expression program [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 868.

A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations

A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations

Author Correction: Failure of Human Rhombic Lip Differentiation Underlies Medulloblastoma Formation

Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in <i>MYCN</i>-amplified neuroblastoma

Recent advances in the developmental origin of neuroblastoma: an overview

Joint single-cell genetic and transcriptomic analysis reveal pre-malignant SCP-like subclones in human neuroblastoma

Abstract 2850: Noncoding regulatory mutations as driving event for the oncogenic core regulatory circuitries of neuroblastoma

A spatial cell atlas of neuroblastoma reveals developmental, epigenetic and spatial axis of tumor heterogeneity

Abstract 149: Modeling patient-specific CHEK2 genetic variants associated with high-risk neuroblastoma

Medulloblastoma oncogene aberrations are not involved in tumor initiation, but essential for disease progression and therapy resistance

Single-Cell Characterization of Malignant Phenotypes and Developmental Trajectories of Adrenal Neuroblastoma

Single-cell RNA sequencing explored potential therapeutic targets by revealing the tumor microenvironment of neuroblastoma and its expression in cell death

Expansion of a neural crest gene signature following ectopic MYCN expression in sympathoadrenal lineage cells in vivo

Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes

The Mutational Landscape of MYCN, Lin28b and ALKF1174L Driven Murine Neuroblastoma Mimics Human Disease.

Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma

Integrative genomic analyses identify neuroblastoma risk genes involved in neuronal differentiation

Abstract 868: A novel unsupervised machine learning model applied to neuroblastoma single-cell RNA-seq data reveals a drug-induced mesenchymal-like gene expression program

Human Fetal Cerebellar Cell Atlas Informs Medulloblastoma Origin and Oncogenesis

Intratumour diversity of chromosome copy numbers in neuroblastoma mediated by on-going chromosome loss from a polyploid state